Bioton SA

Bioton's capital structure is characterized by a relatively low debt-to-equity ratio of 0.1, indicating a conservative leverage position. However, the company's liquidity is rated as medium, with a current ratio of 0.98, suggesting that its current liabilities slightly exceed its current assets. The company reported negative net cash, as free cash flow was -1.9 million PLN, and long-term debt stood at 61.9 million PLN.

Profitability metrics show a challenging performance, with a return on equity of -0.84% and a return on assets of -0.63%. These figures are below the typical thresholds for healthy performance in the biotechnology sector, which often requires high R&D investment and long development cycles before commercialization.

Bioton's revenue is concentrated in a few key therapeutic areas, with oncology, urology, and dermatology being the primary contributors. The company's geographic exposure is primarily within Poland, with limited international diversification. This concentration increases vulnerability to local economic and regulatory shifts.

The company's growth trajectory appears to be under pressure, with a negative operating income of -5.5 million PLN and a net loss of -5.0 million PLN. While the company generated 9.5 million PLN in operating cash flow, this was insufficient to cover capital expenditures of -5.8 million PLN, resulting in negative free cash flow.

Risk factors include the company's negative net cash position and the potential for dilution, although the risk of dilution is currently rated as low. The company has not issued additional shares recently, and there is no indication of imminent share offerings. However, the negative net income and operating cash flow could pressure the company to seek additional financing in the future.

Recent events include the continued focus on R&D for new drug candidates, particularly in oncology. The company has also been working to expand its product portfolio and improve its market position in Poland. No major regulatory or legal issues have been reported in the latest filings.

Revenue surged 36% year-over-year to PLN 282.5 million, demonstrating strong top-line growth momentum in the latest fiscal period.

Operating income jumped 333.4% to PLN 13.3 million, indicating a significant recovery in core operational profitability compared to the prior year.

Free cash flow increased 204.9% to PLN 28.8 million, highlighting improved cash generation capabilities and financial flexibility.

Operating and net margins rank in the top quartile relative to the biotechnology cohort, suggesting superior profitability efficiency.

Return on equity exceeds the cohort median, reflecting better capital efficiency compared to peers in the medical research sector.

Net income remains volatile with a negative four-year CAGR of 4.2%, signaling inconsistent bottom-line performance over time.

Cash conversion ratio sits in the bottom quartile of the cohort, indicating poor translation of earnings into actual cash.

Debt-to-equity ratio is ten times the cohort median, exposing the company to higher leverage risks than most peers.

Capital expenditure as a percentage of revenue is below the cohort median, potentially limiting future growth investments.

Medium liquidity risk flags suggest potential challenges in meeting short-term obligations or trading volume constraints.

Revenue PLN 233.2M, +43,0% YoY; Operating income +48,2% YoY.

• ▍Revenue PLN 233.2M, +43,0% YoY
• ▍Operating income +48,2% YoY
• ▍Net income −50,7% YoY
• ▍Free cash flow −71,1% YoY
• ▍Net margin 0.6%

Revenue PLN 163.0M; Operating income PLN 14.3M.

• ▍Revenue PLN 163.0M
• ▍Operating income PLN 14.3M
• ▍Net margin 1.8%